33. Breast. 2018 Jun;39:14-18. doi: 10.1016/j.breast.2018.02.027. Epub 2018 Mar 7.Endocrine therapy and palbociclib within a compassionate use program in heavilypretreated hormone receptor-positive, HER2-negative metastatic breast cancer.Maurer C(1), Ferreira AR(2), Martel S(3), Lambertini M(4), Pondé N(5), AftimosP(5), de Azambuja E(5), Piccart M(5).Author information: (1)Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Department I of Internal Medicine and Center ofIntegrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.Electronic address: Christian.Maurer@uk-koeln.de.(2)Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Medical Oncology Department, Hospital de Santa Maria and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade deLisboa, Lisbon, Portugal.(3)Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Département d'hémato-oncologie, CISSSMontérégie-centre/Hôpital Charles-Lemoyne, centre affilié de l'Université deSherbrooke, Greenfield Park, Qc, Canada.(4)Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Breast Cancer Translational Research Laboratory,Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium.(5)Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium.This is a single center retrospective analysis of patients with hormonereceptor-positive, HER2-negative metastatic breast cancer progressing after ≥ 4treatment lines treated with palbociclib in combination with endocrine therapywithin a compassionate use program. Thirty-four patients were included between10/2015 and 02/2017, the majority (82.4%) being previously treated with mTORinhibitors. Disease control rate was 52.9% and 24.4% at week 12 and 24. Overallprogression-free survival was 3.1 months with no difference between mTORinhibitor-pretreated (3.5 months) and -naïve patients (2.7 months; hazard ratio, 0.83). Toxicity profile in this population was comparable to that seen inprevious trials.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.breast.2018.02.027 PMID: 29474991 